Oxford Pharmascience Group PLC OXP to exhibit at the Master Investor Show 2016 (0917W)
April 22 2016 - 7:18AM
UK Regulatory
TIDMOXP
RNS Number : 0917W
Oxford Pharmascience Group PLC
22 April 2016
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
To exhibit at the Master Investor Show 2016
Oxford Pharmascience, the specialty pharmaceutical company that
redevelops medicines to make them better, safer and easier to take,
today announces it will be exhibiting at this year's Master
Investor Show held at the Business Design Centre in Islington,
London, on Saturday 23 April 2016.
The Company's CEO, Marcelo Bravo, will be presenting at the
event at 3:30 p.m. and will be at stand number 63 throughout the
day. The presentation has been uploaded to the Company's website at
www.oxfordpharmascience.com.
Summarising recent progress, Marcelo Bravo said:
"Our lead NSAID products, OXPzero(TM) Ibuprofen and OXPzero(TM)
Naproxen, are now at the commercialisation stage. We are very
encouraged with the strong traction we are getting from some of the
major potential partners in our discussions.
In addition to the recent confirmation from the MHRA on the
simplified regulatory pathway for OXPzero(TM) Ibuprofen, which we
believe will also apply to OXPzero(TM) Naproxen, we are continuing
to progress our other pipeline opportunities, including Aspirin and
statins. Our strong financial position supports our combined
strategy of commercialising our NSAID assets and platform and
advancing our other pipeline compounds."
A short update video is available at the following link
below:
http://brrmedia.co.uk/event/141808
For further information:
Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive +44 20 7554 5875
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Jen Boorer +44 20 7496 3000
Redleaf Communications
Hannah Nicolas / Lara Pyliotis +44 20 7382 4734
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc uses a range of proprietary
technology platforms to re-develop existing medicines to make them
better, safer or easier to take. The Company does not manufacture
or sell its own pharmaceutical products direct to consumers, but
instead seeks to license its technologies and dossiers to a network
of partners, mainly leading pharmaceutical companies with Rx
(prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience Group Plc focuses on existing medicines
that are proven to be safe and effective but nevertheless still
have associated issues and side effects often affecting compliance.
By working with such medicines, the Company is able to develop new
innovative products for a fraction of the cost, in much quicker
timescales and without the high risk of failure associated with
developing new drugs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCMMGZDMZVGVZM
(END) Dow Jones Newswires
April 22, 2016 07:18 ET (11:18 GMT)
Alba (LSE:ABA)
Historical Stock Chart
From Apr 2024 to May 2024
Alba (LSE:ABA)
Historical Stock Chart
From May 2023 to May 2024